GLP-1 Resource Center

What is the difference between Ozempic and Wegovy?

Ozempic and Wegovy contain the same active ingredient, semaglutide, but they are different products approved for different purposes at different doses. Understanding the distinction clarifies what you are taking, and why the nutritional consequences are similar regardless of which you are prescribed.

The same molecule, different doses

Both Ozempic and Wegovy are injectable semaglutide manufactured by Novo Nordisk. Ozempic is FDA-approved for type 2 diabetes management and cardiovascular risk reduction. Wegovy is FDA-approved specifically for chronic weight management in adults with obesity, or overweight with at least one weight-related health condition. The key difference is maximum dose: Ozempic goes up to 2mg weekly, Wegovy goes up to 2.4mg weekly. In STEP 1 (Wilding et al., NEJM 2021), semaglutide 2.4mg weekly produced an average loss of 14.9 percent of body weight over 68 weeks.

Why Ozempic is frequently prescribed off-label for weight loss

Ozempic is commonly prescribed off-label for weight loss in patients who do not qualify for or cannot access Wegovy. The mechanism is identical and the weight loss outcomes at comparable doses are similar. At 1mg weekly, Ozempic is associated with approximately 10 to 12 percent body weight reduction in clinical trials. The distinction is regulatory, not pharmacological.

Mounjaro and Zepbound: the tirzepatide comparison

Mounjaro and Zepbound contain tirzepatide, a dual GIP and GLP-1 receptor agonist manufactured by Eli Lilly. Tirzepatide activates two hormone pathways rather than one, and trials report greater average weight loss than semaglutide alone. In SURMOUNT-1 (Jastreboff et al., NEJM 2022), tirzepatide 15mg weekly produced an average loss of 22.5 percent of body weight, against 14.9 percent for semaglutide 2.4mg in STEP 1. These are separate trials in different populations rather than a head-to-head comparison, so read the gap as indicative rather than exact. The nutritional consequences of tirzepatide are similar to semaglutide: reduced food intake, lower micronutrient intake, digestive change, and lean mass risk.

What is consistent across all GLP-1 medications

Regardless of whether you are on Ozempic, Wegovy, Mounjaro, or Zepbound, the nutritional consequences of significantly reduced food intake are the same. A 2025 joint advisory from four professional societies (Mozaffarian et al., Obesity) reported caloric intake reductions of 16 to 39 percent across the GLP-1 drug class. Lower micronutrient and electrolyte intake, digestive change, lean mass risk, hair shedding, sleep changes, and fatigue are not specific to one medication. They follow from the reduced caloric intake these medications produce.

Lean mass is the one place the medications differ

Across GLP-1 trials the share of weight lost as lean mass depends on the medication: about 26 percent on tirzepatide, and up to 45 percent on semaglutide, with a class-wide average near 30 percent and reported figures ranging from 20 to 50 percent.* The tirzepatide figure comes from the SURMOUNT-1 DXA substudy (Look et al., Diabetes, Obesity and Metabolism, 2025), which enrolled 255 participants and analysed 160, and reported 74 percent of the body weight reduction as fat mass and 26 percent as lean mass. The class-wide picture comes from a 2026 systematic review and meta-analysis in the International Journal of Obesity covering seven studies and 821 patients, which placed liraglutide at 14 to 22 percent, tirzepatide at about 26 percent and semaglutide at up to 45 percent.

Two things make that read less alarming than it first appears. In SURMOUNT-1 the placebo group lost the same ratio, 25 percent against 26 percent, so this is weight loss behaving as weight loss rather than the medication doing something unusual. And fat-free mass measured by DXA includes water, glycogen and connective tissue, so it is not skeletal muscle alone. The 20 to 50 percent range reported across the literature is in line with what is seen after diet-induced weight loss and after bariatric surgery.

Hold the comparison loosely. Tirzepatide is associated with more total weight loss (22.5 percent against 14.9 percent) and a lower share of that loss as lean mass, but those numbers come from separate trials in different populations rather than head-to-head studies, and individual results vary considerably. Which medication is right for you is a conversation with your prescriber, informed by your history and your bloodwork.

The TAKE approach

TAKE Essentials are formulated for people on any GLP-1 medication, semaglutide or tirzepatide, because the nutritional consequences are consistent across the class.* What you actually need is a matter for your bloodwork and your clinician. View The Eight Essentials. Not sure where to start? Visit the GLP-1 Resource Center.

These statements have not been evaluated by the Food and Drug Administration. TAKE products are not intended to diagnose, treat, cure, or prevent any disease. Individual results vary. Always speak with your healthcare provider about medication side effects or medical concerns.